Healthcare
Windlas Biotech Limited (windlas) Q1fy27: Revenue Streak Extends to 14 Quarters with 18% Yoy Growth
Windlas Biotech Limited (WINDLAS) reports Q1FY27 results with 18% YoY revenue growth to Rs 248 crore, EBITDA up 26%, and PAT up 37%.
Windlas Biotech Limited (WINDLAS) has started FY27 with a positive note by extending its record revenue streak to 14 consecutive quarters with an impressive 18% year-on-year growth to Rs 248 crore in Q1FY27. Consistent with its focus on long-term shareholders value creation, in Q1FY27 the company also completed a ₹47 crore buyback in which promoters did not participate and declared a FY26 dividend of ₹13 crore (₹6.30 per equity share).
Financial Highlights
Excluding the impact of Non-cash ESOP expenses (₹7.2 crore) which are non-cash in nature, our EBITDA grew 26% YoY to ₹34 crore, PBT and PAT grew 27% and 37% YoY to ₹30 crore and ₹25 crore respectively, reflecting our continued focus on improving operational leverage. If we take into account Non-cash ESOP expenditure (₹7.2 crore), the company reported EBITDA ₹27 crore, PBT ₹23 crore, and PAT ₹18 crore. For Q1FY27 Earnings Per Share (EPS) has improved to ₹8.46.
Vertical Performance
Our Generic Formulations CDMO vertical delivered 29% YoY revenue growth to ₹207 crore, driven by customer expansion, deeper customer engagement, and new product launches. The Trade Generics & Institutional vertical reported revenue of ₹30 crore, following the discontinuation of codeine-based products. As we expand the portfolio with new launches and replacements, we expect to progressively bridge the gap. Our Exports vertical recorded 79% YoY growth to ₹11 crore.
Looking ahead, our priorities remain focused on strengthening strategic partnerships, expanding our offerings, achieving operational excellence, accelerating portfolio development, and driving disciplined execution. Supported by a modernized manufacturing base, a talented workforce, and a clear strategic direction, we are well positioned to capitalize on the opportunities across all three business verticals.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Windlas Biotech Limited
Windlas Biotech Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Windlas moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 7.4% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The business compounds revenue at 20.7% and profits at 16.0% CAGR. That is strong double-digit growth on both counts. The stock holds at 46% of its 52-week range with RSI at 61. In other words, neither side has a clear edge right now. Revenue grows at 20.7% and profits at 16.0%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Windlas Biotech Limited.
Healthcare
Zydus Lifesciences Limited (zyduslife) Inspection by USFDA Concludes at Liqmeds, UK
Zydus Lifesciences Limited (ZYDUSLIFE) announces the closure of USFDA inspection at LiqMeds, UK with 4 observations.
Zydus Lifesciences Limited (ZYDUSLIFE) announced the closure of a USFDA inspection at LiqMeds, UK. The inspection took place from 9th to 13th November 2026 and concluded with four observations. The company will work closely with the USFDA to address these observations expeditiously.
Inspection Details
The USFDA conducted an inspection at LiqMeds, UK, focusing on compliance and operational standards. The four observations noted during the inspection will be addressed promptly to ensure full compliance with regulatory requirements.
Company’s Response
Zydus Lifesciences Limited is committed to maintaining high standards of quality and compliance. The company will collaborate closely with the USFDA to resolve the observations identified during the inspection. This proactive approach aims to expedite the resolution process and uphold the company’s reputation for quality and integrity.
As a result, Zydus Lifesciences Limited remains focused on its mission to deliver high-quality pharmaceutical products globally. The company’s dedication to addressing regulatory observations underscores its commitment to continuous improvement and adherence to international standards.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Zydus Lifesciences Limited
Zydus Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Zydus holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.67 signals undervaluation relative to growth. It is a potential re-rating candidate. The business compounds revenue at 16.5% and profits at 37.0% CAGR. That is strong double-digit growth on both counts. The stock trades at 70% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Revenue grows at 16.5% and profits at 37.0%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Zydus Lifesciences Limited.
ALKEM
Alkem Laboratories Limited Q2fy27: Revenue Growth of 14%
Alkem Laboratories Limited (ALKEM) reports 14% revenue growth in Q2FY27, with strong performance in both domestic and international segments.
Alkem Laboratories Limited (NSE: ALKEM) announced its standalone and consolidated financial results for the second quarter ended September 30, 2026, reflecting a robust performance. The Board of Directors reviewed these results at its meeting held in Mumbai today. Commenting on the results, Mr. Sandeep Singh, Managing Director of Alkem, stated, “Our Q2FY27 performance reflects continued momentum in the India business, supported by focused execution across our acute and chronic portfolios. The international business delivered steady progress despite continued pricing pressure in the US, with volume growth providing support.”
Q2FY27 Key Financial Highlights
Total Revenue from Operations was ₹45,520 million, with a year-on-year growth of 13.8%. India sales were ₹30,275 million, showing a YoY growth of 9.5%. International sales were ₹14,540 million, with a YoY growth of 22.3%. EBITDA at ₹10,252 million resulted in an EBITDA margin of 22.5%, a growth of 11.3% YoY. Profit before tax (before exceptional item) was ₹9,646 million, with a YoY growth of 7.7%. Net Profit (after Non-Controlling interest) was ₹6,753 million, with a YoY de-growth of 11.7%.
Operational Highlights
The contribution of domestic sales to total sales was 68% vs. 70% in Q2 FY26. US sales were ₹7,830 million, with a YoY growth of 2.4%. Non-US sales were ₹6,710 million, with a YoY growth of 58%.
For more information, please visit www.alkemlabs.com and follow us on LinkedIn, Instagram, and Facebook.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Alkem Laboratories Limited
Alkem Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Alkem moves sideways over three months, with neither buyers nor sellers taking control. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The PEG of 0.92 signals undervaluation relative to growth. It is a potential re-rating candidate. The stock gains 4.7% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 8.3% and profits at 32.7%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Alkem Laboratories Limited.
Healthcare
Suven Life Sciences Limited to Present Seven Scientific Posters at Neuroscience 2026
Suven Life Sciences Limited (SUVEN) to present seven scientific posters at Neuroscience 2026, showcasing CNS drug discovery.
Suven Life Sciences Limited (SUVEN) announced its participation in Neuroscience 2026, the annual meeting of the Society for Neuroscience (SfN), to be held in Washington, DC, USA, from November 14-18, 2026. The company will present seven scientific posters highlighting its drug discovery and development programs targeting central nervous system (CNS) disorders.
Diverse Portfolio of Drug Candidates
The presentations span a diverse range of therapeutic areas, including Alzheimer’s Disease, Agitation, Schizophrenia, Narcolepsy, Sleep Disorders, Major Depressive Disorder, and Parkinson’s Disease. The posters highlight Suven’s continued progress in advancing innovative drug candidates through clinical and preclinical development.
Key Presentations
Suven will present the following seven posters: SUVN-M8036: A Multimodal Receptor Antagonist That Exhibits Antipsychotic and Anti-Aggressive-Like Effects in Animal Models; SUVN-I6107 (Tenaclidine): Safety, Tolerability, and Pharmacokinetics of a Pure M1 Positive Allosteric Modulator: Results from a First-in-Human Study in Healthy Subjects; SUVN-L1101142: A Novel Muscarinic M4 Positive Allosteric Modulator for the Treatment of Alzheimer’s Disease and Schizophrenia; Samelisant: Efficacy and Safety of an H3 Receptor Inverse Agonist for the Treatment of Narcolepsy With or Without Cataplexy: A Phase 3 Study; SUVN-N9503012: Efficacy of a Selective 5-HT1A Receptor Partial Agonist Intended for the Treatment of L-Dopa-Induced Dyskinesia; Ropanicant (SUVN-911): A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety in Patients with Major Depressive Disorder; Masupirdine (SUVN-502): Baseline Characteristics from a Phase-3 Study in Alzheimer’s Dementia with Agitation.
Suven’s participation at Neuroscience 2026 reflects the breadth and continued progress of its CNS research and development pipeline. The company remains committed to advancing innovative therapies that address significant unmet medical needs, improve outcomes for patients, and create long-term value for the company.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Suven Life Sciences Limited
Suven Life Sciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Suven falls 14.9% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 5 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock holds at 55% of its 52-week range with RSI at 37. In other words, neither side has a clear edge right now. The stock holds up despite -19.3% revenue growth and a PEG of 99.00. That could signal an early turnaround. Alternatively, index flows simply support the price. Watch whether analysts revise estimates upward — that is the real signal. Check Fundamentals of Suven Life Sciences Limited.
-
ECLERX3 days agoEclerx Services Limited (eclerx) Announces Acquisition of Regedge
-
Information Technology Services3 days agoLtm Limited (LTM) Introduces Ai-powered Quantum Error Mitigation to IBM Quantum Functions Catalog
-
RATEGAIN3 days agoRategain Travel Technologies Limited (NSE: Rategain) Partners with Uzbekistan Airways to Enhance Pricing Agility
-
Basic Materials2 days agoPrakash Industries Limited (prakash) Q2fy2027: Net Sales Up 24%, Ebitda Rises 30%
-
GREENPOWER3 days agoOrient Green Power Company Limited (greenpower) Q2 FY27: ₹106 Cr Net Profit, 76% Ebitda Margin
-
GAIL3 days agoGail (india) Limited Signs Mou with Krishak Bharati Cooperative for Andhra Pradesh Fertilizer Project
-
ABCAPITAL3 days agoAditya Birla Capital Limited (abcapital) Inaugurates its 100th Dedicated Gold Loan Branch
-
Basic Materials3 days agoMan Industries (india) Limited Q2 FY27: Delivers Highest Ever Core Business Ebitda